Haematologica (May 2015)

Current outcome of HLA identical sibling versus unrelated donor transplants in severe aplastic anemia: an EBMT analysis

  • Andrea Bacigalupo,
  • Gerard Socié,
  • Rose Marie Hamladji,
  • Mahmoud Aljurf,
  • Alexei Maschan,
  • Slawomira Kyrcz-Krzemien,
  • Alicja Cybicka,
  • Henrik Sengelov,
  • Ali Unal,
  • Dietrich Beelen,
  • Anna Locasciulli,
  • Carlo Dufour,
  • Jakob R. Passweg,
  • Rosi Oneto,
  • Alessio Signori,
  • Judith C.W. Marsh,
  • for the Aplastic Anemia Working Party of the European Group for Blood Marrow Transplantation (WPSAA-EBMT)

DOI
https://doi.org/10.3324/haematol.2014.115345
Journal volume & issue
Vol. 100, no. 5

Abstract

Read online

We have analyzed 1448 patients with acquired aplastic anemia grafted between 2005 and 2009, and compared outcome of identical sibling (n=940) versus unrelated donor (n=508) transplants. When compared to the latter, sibling transplants were less likely to be performed beyond 180 days from diagnosis (39% vs. 85%), to have a cytomegalovirus negative donor/recipient status (15% vs. 23%), to receive antithymocyte globulin in the conditioning (52% vs. 61%), and more frequently received marrow as a stem cell source (60% vs. 52%). Unrelated donor grafts had significantly more acute grade II–IV (25% vs. 13%) and significantly more chronic graft-versus-host disease (26% vs. 14%). In multivariate analysis, the risk of death of unrelated donor grafts was higher, but not significantly higher, compared to a sibling donor (P=0.16). The strongest negative predictor of survival was the use of peripheral blood as a stem cell source (P